AIDS Malignancy Consortium Clinical Trials
Sponsors / AIDS Malignancy Consortium
ClinicalTrials.gov lists 57 trials for which AIDS Malignancy Consortium is named as lead sponsor. The portfolio currently includes 5 recruiting studies, 2 active non-recruiting studies, and 40 completed studies. 6 trials in this portfolio were terminated or withdrawn before completion. The most common reasons cited for termination include slow or insufficient recruitment. Cumulative planned enrollment across all listed trials is 8,831 participants. These counts reflect the current state of the public ClinicalTrials.gov registry.
57
Total Trials
5
Recruiting
2
Other Active
40
Completed
6
Terminated / Withdrawn
8,831
Total Enrollment
Termination reasons: Recruitment50% · Other50%
Recent Terminations
- NCT02823327 Stopped Feb 2023AIDS-Related Primary Effusion Lymphoma"Poor accrual"
- NCT01567722 Stopped Jan 2022Lung Cancer"Sponsor directive"
- HIV Infection"Inadequate accrual rate"
- NCT01319526 Stopped Jan 2013Lymphoma"Parent protocol (SWOG S0816 / AMC-073) discontinued"
- Sarcoma"Terminated due to slow accrual."
- Kaposi's Sarcoma"Drug supply unavailable."
Active Trials (2 total)
- NCT05077527
- Kaposi Sarcoma PHASE2NCT04305691
- NCT04949464
- NCT05663502
- Ann Arbor Stage I Diffuse Large B-Cell Lymphoma EARLY_PHASE1NCT04139304
- HIV Infection PHASE1/PHASE2NCT02797470
- Anal Squamous Cell Carcinoma PHASE2NCT02437851